PatientsLikeMe for Partners Blog

News Release: Survey Reveals PatientsLikeMe® Helps People With Epilepsy Improve Seizure Understanding and Medication Adherence

In today’s news…

********

BRUSSELS, BELGIUM and CAMBRIDGE, MA–(Marketwire – April 12, 2011) – In a survey amongst people with epilepsy in the U.S. who have joined PatientsLikeMe®, thepilespyprofilee leading health data-sharing website for patients, respondents indicate that better seizure understanding and improved adherence are key benefits of using the site. The majority of respondents (55%) indicate a better understanding of their seizures, while one in four (27%) report improved adherence to treatment as a result of joining the PatientsLikeMe epilepsy community. When asked about their social interactions with other patients, one in three respondents (30%) said they did not know a single other person with epilepsy before joining the site; 63% of these said they were now communicating with one or more patients on the site.

The complete results from this survey of 221 epilepsy patients are being presented this week at the annual meeting of the American Academy of Neurology, in Hawaii, U.S. (April 9th-16th). In early 2010, PatientsLikeMe and UCB first invited U.S. epilepsy patients to share their seizure experiences, symptoms and treatments through the website; there are more than 3,600 members to date. UCB receives annonymized, aggregated data from the PatientsLikeMe epilepsy community…. >> Click here to see the full news release.

Leave a Comment

NOTE: You’ve got something to say and we want to hear it. If you’d like your comment to be displayed here, please follow these guidelines:

  1. Be nice. Expressing your opinion is encouraged, but rude, inflammatory or inappropriate comments are not allowed.
  2. Add value. Submit comments that are clear and stay on topic.
  3. Be patient. We publish comments a few times per week.
  4. Know where you are. This is an open blog that everyone on the Internet can read. Your comments may be repurposed and used elsewhere (e.g., Twitter, Facebook, etc.).

Thanks again for sharing your insights and opinions with us and our readers!